Workplace Migraine Burden Underscores Market Potential for ShiraTronics

According to a recent LinkedIn post from ShiraTronics, a newly published study in Headache: The Journal of Head & Face Pain is cited as finding that employees with migraine may lose about 10 days of productive time per year. The post notes that most of this loss is attributed to presenteeism rather than absenteeism, implying substantial hidden productivity costs for employers.

The LinkedIn post highlights that in a survey of over 33,000 employees at a large U.S. healthcare system, nearly 60% of respondents screened positive for migraine, yet only about half answered basic migraine knowledge questions correctly. The content suggests migraine may be significantly underrecognized and undermanaged in the workplace during individuals’ peak productive years.

As shared in the post, ShiraTronics characterizes migraine as a neurological disease and positions its mission around helping patients regain productivity, focus, and quality of life. For investors, this framing underscores a potentially large addressable market tied to workplace productivity, particularly if employers increasingly prioritize solutions that can mitigate migraine-related performance losses.

The emphasis on presenteeism and broad prevalence could imply growing demand for more effective migraine interventions, including neuromodulation or other advanced therapies where companies like ShiraTronics may be active. If these data points gain wider traction among corporate health decision-makers, ShiraTronics could benefit from heightened interest in tools that reduce migraine burden and related economic impact.